Cumberland Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CUMBERLAND, and when can generic versions of CUMBERLAND drugs launch?
CUMBERLAND has eight approved drugs.
There are seventeen US patents protecting CUMBERLAND drugs.
There are one hundred and thirty-one patent family members on CUMBERLAND drugs in thirty-eight countries and fourteen supplementary protection certificates in twelve countries.
Summary for Cumberland
| International Patents: | 131 |
| US Patents: | 17 |
| Tradenames: | 9 |
| Ingredients: | 8 |
| NDAs: | 8 |
Drugs and US Patents for Cumberland
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-003 | Jan 25, 2019 | RX | Yes | Yes | 11,806,400 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Cumberland | VAPRISOL | conivaptan hydrochloride | INJECTABLE;INTRAVENOUS | 021697-001 | Dec 29, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-003 | Jan 25, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Cumberland Pharms | LACTULOSE | lactulose | FOR SOLUTION;ORAL | 074712-001 | Dec 10, 1997 | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-003 | Jan 25, 2019 | RX | Yes | Yes | 8,735,452 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Cumberland | SANCUSO | granisetron | FILM, EXTENDED RELEASE;TRANSDERMAL | 022198-001 | Sep 12, 2008 | RX | Yes | Yes | 7,608,282 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-002 | Jun 11, 2009 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Cumberland
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-002 | Jun 11, 2009 | 6,727,286 | ⤷ Try a Trial |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 7,208,471 | ⤷ Try a Trial |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 6,635,618 | ⤷ Try a Trial |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | 8,101,575 | ⤷ Try a Trial |
| Cumberland | VAPRISOL | conivaptan hydrochloride | INJECTABLE;INTRAVENOUS | 021697-001 | Dec 29, 2005 | 5,723,606 | ⤷ Try a Trial |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 7,700,550 | ⤷ Try a Trial |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 8,158,580 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUMBERLAND drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Transdermal System | 3.1 mg/24 hrs | ➤ Subscribe | 2015-10-09 |
| ➤ Subscribe | Injection | 200 mg/mL, 30 mL vials | ➤ Subscribe | 2012-04-04 |
International Patents for Cumberland Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hungary | E026769 | ⤷ Try a Trial |
| Canada | 2726967 | ⤷ Try a Trial |
| Poland | 379027 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2010105129 | ⤷ Try a Trial |
| Spain | 2477268 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2011008347 | ⤷ Try a Trial |
| Australia | 2016203946 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cumberland Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1292612 | PA2012002 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902 |
| 1292612 | SPC/GB11/056 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTERED: UK EU/1/11/705/001 20110906; UK EU/1/11/705/002 20110906 |
| 1292612 | CA 2011 00033 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID |
| 1292612 | 2011/037 | Ireland | ⤷ Try a Trial | PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
| 1292612 | 122011100062 | Germany | ⤷ Try a Trial | PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
| 1292612 | 132012902025885 | Italy | ⤷ Try a Trial | PRODUCT NAME: TELAVANCINA(VIBATIV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/705/001-002, 20110902 |
| 1292612 | 1190036-2 | Sweden | ⤷ Try a Trial | PRODUCT NAME: TELAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV INNEFATTANDE TELAVANCINHYDROKLORID; REG. NO/DATE: EU/1/11/705/001 20110902 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
